Next 10 |
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS PR Newswire Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , Ap...
2024-03-05 22:06:02 ET Cumberland Pharmaceuticals Inc. (CPIX) Q4 2023 Earnings Conference Call March 05 2024 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman and Chief Executive Officer Todd Anthony - Vice P...
2024-03-05 16:13:46 ET More on Cumberland Pharmaceuticals Financial information for Cumberland Pharmaceuticals Read the full article on Seeking Alpha For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of $0.17, revenue of $40M
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results PR Newswire 2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a sp...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceuticals company, announced today that it will release its an...
2023-12-14 17:28:56 ET More on Cumberland Pharmaceuticals Cumberland Pharmaceuticals Q3 2023 Earnings Call Transcript Cumberland Pharmaceuticals 2023 Q3 - Results - Earnings Call Presentation Financial information for Cumberland Pharmaceuticals For further de...
2023-11-11 08:17:06 ET Cumberland Pharmaceuticals Inc. (CPIX) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A. J. Kazimi - Chairman and Chief Executive Officer Todd Anthony - Vice...
2023-11-07 16:43:48 ET Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): Q3 Non-GAAP EPS of $0.02. Revenue of $10.1M (-11.4% Y/Y). Company ended the third quarter with $88 million in total assets, $52 million in total liabilities, and $36 million of shareholde...
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results PR Newswire NASHVILLE, Tenn. , Nov. 7, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, announced today that its product portfolio...
News, Short Squeeze, Breakout and More Instantly...
Cumberland Pharmaceuticals Inc. Company Name:
CPIX Stock Symbol:
NASDAQ Market:
Cumberland Pharmaceuticals Inc. Website:
NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS PR Newswire Growing data shows intravenous ibuprofen is safe and effective for the treatment of pain and fever in adults, children and infants NASHVILLE, Tenn. , Ap...
Cumberland Pharmaceuticals Reports Annual 2023 Financial Results PR Newswire 2023 highlights include expanded FDA approval and new study publications NASHVILLE, Tenn. , March 5, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a sp...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...